Alpha-fetoprotein peptide–human leukocyte antigen A2 complex (null)

The **Alpha-fetoprotein peptide–human leukocyte antigen A2 complex** is an immunological target composed of a processed peptide from alpha-fetoprotein (a fetal and tumor-associated glycoprotein) bound to the MHC class I molecule HLA-A2 on cell surfaces[3]. This complex can be recognized by cytotoxic T cells, making it a focal point in the design of cancer immunotherapies, especially vaccines and TCR-based therapeutics for hepatocellular carcinoma and certain other tumors overexpressing AFP[3]. HLA-A2-restricted AFP peptides have been identified that stimulate strong immune responses, and their stable binding with HLA-A2 is critical for effective antigen presentation and therapy[3]. The complex itself is not a naturally occurring receptor or enzyme but a synthetic or induced antigenic target relevant to immunotherapy.

Other names

AFP peptide–HLA-A2 complexAFP/HLA-A*0201 complexAlpha-fetoprotein-derived peptide–HLA-A2 complex

Presentation of tumor-associated alpha-fetoprotein peptide to CD8+ T cells via HLA-A2, leading to cytotoxic T lymphocyte recognition and potential tumor cell killing[3].